Sort
39,280 grants matching “leukemia”
Mechanisms and Consequences of NOTCH Dysfunction in Head and Neck Cancer
$400,000Mitchell J. Frederick · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · DE
Epithelial mechanisms of inducible resistance to AML-associated pneumonia
$400,000Scott E. Evans · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · HL
A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma
$400,000David Scott Johnson · Gigamune, Inc. · R44 · FY2025 · CA
Immune privilege of the hematopoieitic stem cell niche
$400,000Joji Fujisaki · Columbia University Health Sciences · R01 · FY2018 · HL
Gene and Cytokine Expression in Tolerance and GVHD
$400,000Samuel Strober · Stanford University · R01 · FY2009 · AI
UCCRC -Cancer Center Support Grant
$400,000University Of Chicago · P30 · FY2003 · CA
Epithelial mechanisms of inducible resistance to AML-associated pneumonia
$400,000Scott E. Evans · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · HL
Early T Lineage Progenitors
$400,000Mark I Greene · University Of Pennsylvania · R56 · FY2014 · AI
Kansas City Clincal Oncology Program CCOP
$400,000Rakesh Gaur · Nci Community Oncology Research Program · U10 · FY2012 · CA
Mechanisms and Consequences of NOTCH Dysfunction in Head and Neck Cancer
$400,000Mitchell J. Frederick · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · DE
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition
$400,000Mengqian Chen · Senex Biotechnology, Inc. · R43 · FY2022 · CA
Immune privilege of the hematopoieitic stem cell niche
$400,000Joji Fujisaki · Columbia University Health Sciences · R01 · FY2019 · HL
CAREER: Advancing Model Predictive Control of Cell Differentiation
$400,000Ann Rundell · Purdue University · · FY2009 · ENG
Molecular Characterization of Predatory Stem Cells in a Chimeric Protochordate
$400,000Irving Lerner Weissman · Stanford University · R56 · FY2010 · AI
Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy
$400,000Amanda M Schalk · Enzyme By Design, Inc. · R43 · FY2024 · CA
Ehrlichia Notch SLiM-activated oncoprotein inhibition of apoptosis
$400,000Jere W McBride · University Of Texas Med Br Galveston · R01 · FY2022 · AI
Immune privilege of the hematopoieitic stem cell niche
$400,000Joji Fujisaki · Columbia University Health Sciences · R01 · FY2016 · HL
Mechanisms of Parp inhibitor-induced bone marrow toxicities
$400,000Jane Ellen Churpek · University Of Wisconsin-Madison · R01 · FY2023 · HL
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD
$400,000Leslie S Kean · Seattle Children'S Hospital · R01 · FY2016 · FD
UCCRC -Cancer Center Support Grant
$400,000University Of Chicago · P30 · FY2002 · CA
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD
$400,000Leslie S Kean · Seattle Children'S Hospital · R01 · FY2014 · FD
Molecular Analysis of Hindbrain Formation
$400,000Charles G Sagerstrom · Univ Of Massachusetts Med Sch Worcester · R56 · FY2007 · NS
Yes1 as a quiescence regulator in hematopoietic stem cells
$400,000Siddhartha Mukherjee · Columbia University Health Sciences · R01 · FY2017 · HL
Cancer Center Support Grant (CCSG)
$400,000George J Weiner · University Of Iowa · P30 · FY2016 · CA
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
$400,000Aaron D Schuler · Syntrix Biosystems, Inc. · R44 · FY2024 · CA